Zenas BioPharma, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Zenas BioPharma, Inc. (ZBIO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$388.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-16
- Zenas BioPharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$388.51M.
- Zenas BioPharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$160.92M.
- Zenas BioPharma, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$10.85M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$388.51M 10-K · filed 2026-03-16 |
| 2024-12-31 | -$160.92M 10-K · filed 2026-03-16 |
| 2023-12-31 | -$10.85M 10-K · filed 2025-03-11 |